223 related articles for article (PubMed ID: 11735110)
21. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.
Hedner U; Glazer S; Falch J
Transfus Med Rev; 1993 Apr; 7(2):78-83. PubMed ID: 8481602
[TBL] [Abstract][Full Text] [Related]
22. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Allen GA; Hoffman M; Roberts HR; Monroe DM
Can J Anaesth; 2002 Dec; 49(10):S7-14. PubMed ID: 12546000
[TBL] [Abstract][Full Text] [Related]
23. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors.
Shapiro AD
Semin Thromb Hemost; 2000; 26(4):413-9. PubMed ID: 11092217
[TBL] [Abstract][Full Text] [Related]
24. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
Seremetis S
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S29-30. PubMed ID: 14567532
[TBL] [Abstract][Full Text] [Related]
25. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
Kessler C
Intensive Care Med; 2002 Oct; 28 Suppl 2():S228-34. PubMed ID: 12404091
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
27. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
28. [Administration of activated recombinant factor VII (novo seven) for the control of massive bleeding in gynecology].
Tanchev S; Pandurski F; Georgiev A; Gesheva Iu; Platikanov V; Dinov P
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():32-5. PubMed ID: 15518274
[TBL] [Abstract][Full Text] [Related]
29. [Use of recombinant factor VIIa for the control of massive bleeding caused by uterine hypotonia in post-placental period].
Tanchev S; Platikanov V; Markova S; Slavov N; Bogdanova A; Dimitrova D
Akush Ginekol (Sofiia); 2004; 43(1):16-20. PubMed ID: 15168648
[TBL] [Abstract][Full Text] [Related]
30. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors.
Lusher JM
Haemostasis; 1996; 26 Suppl 1():124-30. PubMed ID: 8904186
[TBL] [Abstract][Full Text] [Related]
31. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
Veldman A; Hoffman M; Ehrenforth S
Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
[TBL] [Abstract][Full Text] [Related]
32. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII.
Veldman A; Fischer D; Voigt B; Beyer PA; Schlösser R; Allendorf A; Kreuz W
Intensive Care Med; 2002 Nov; 28(11):1635-7. PubMed ID: 12415453
[TBL] [Abstract][Full Text] [Related]
33. NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia.
Franchini M; Lippi G
Expert Rev Hematol; 2014 Dec; 7(6):733-40. PubMed ID: 25387838
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors to Factor XI in patients with severe Factor XI deficiency.
Salomon O; Zivelin A; Livnat T; Seligsohn U
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S10-2. PubMed ID: 16427373
[TBL] [Abstract][Full Text] [Related]
35. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
[TBL] [Abstract][Full Text] [Related]
36. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
Brackmann HH; Effenberger W; Hess L; Schwaab R; Oldenburg J
Eur J Haematol Suppl; 1998; 63():18-23. PubMed ID: 9882928
[TBL] [Abstract][Full Text] [Related]
37. Ultra-early hemostatic therapy for acute intracerebral hemorrhage.
Mayer SA; Rincon F
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S70-6. PubMed ID: 16427389
[TBL] [Abstract][Full Text] [Related]
38. Inhibitor treatment: state of the art.
Shapiro A
Dis Mon; 2003 Jan; 49(1):22-38. PubMed ID: 12525826
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa.
Carr ME; Martin EJ; Kuhn JG; Ambrose H; Fern S; Bryant PC
Clin Lab; 2004; 50(9-10):529-38. PubMed ID: 15481628
[TBL] [Abstract][Full Text] [Related]
40. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
